Milestone Pharmaceuticals MIST 深 滬
等待開盤 10-28 09:30:00 美东时间
0.6912
+0.047
+7.26%
華盛通- 最 高0.696
- 今 開0.65
- 成交量 75.45万股
- 最 低 0.644
- 昨 收 0.6444
- 總市值 8.61万
- 52周最高 3.06
- 市盈率 靜 --
- 換手率 0.61%
- 52周最低 0.6307
- 委 比 -62.89%
- 總股本 0.00亿
- 歷史最高 27.95
- 量 比 0.90
- 振 幅 8.07%
- 歷史最低 0.6254
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Milestone Pharmaceuticals收跌7.76%，成交额103.05万美元
10月24日，Milestone Pharmaceuticals（MIST）收跌7.76%，报0.65美元，成交额103.05万美元，市值8069.92万美元...
10-24 07:11
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
Milestone Pharmaceuticals announced that data and updates for CARDAMYST® (etripamil) nasal spray will be presented at three upcoming cardiovascular meetings: the CAPP National Conference (October 22-24), TCT 2026 (October 31-November 3), and AHA Scientific Sessions 2026 (November 6-9). Presentations will cover PSVT treatment, Phase 3 trial design for atrial fibrillation, and etripamil's efficacy and safety. CARDAMYST is approved for acute PSVT ep...
10-19 12:00
Milestone Pharmaceuticals收跌10.98%，成交额71.74万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:11
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
Milestone Pharmaceuticals announced the enrollment of the first European patient in the Phase 3 ReVeRA-301 trial evaluating etripamil nasal spray for treating atrial fibrillation with rapid ventricular rate (AFib-RVR). The study, led by the Dutch Cardiovascular Investigator Network (WCN), aims to enroll approximately 150 AFib-RVR patients. ReVeRA-301 assesses the same 70 mg repeat-dose regimen approved for paroxysmal supraventricular tachycardia ...
10-09 12:00
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Montreal Heart Institute has joined the ReVeRA-301 Phase 3 trial evaluating etripamil nasal spray for treating atrial fibrillation with rapid ventricular rate (AFib-RVR). The study, which aims to enroll 150 patients globally, is assessing the same 70 mg repeat-dose regimen approved for paroxysmal supraventricular tachycardia (PSVT). The primary endpoint is reducing ventricular rate within 30 minutes, with secondary endpoints focusing on symptom i...
09-24 12:00
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $8 price target.
09-03 23:54
云顶新耀：星必妥新药上市申请获NMPA批准，用于治疗成人PSVT急性症状发作
9月3日，云顶新耀有限公司宣布，中国国家药品监督管理局（NMPA）已批准星必妥（艾曲帕米鼻喷雾剂）的新药上市许可申请，用于治疗成人阵发性室上性心动过速（PSV...
09-03 21:19
Milestone Pharmaceuticals Presenting Data In Moderated EPoster Session Titled 'he Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes' At European Society Of Cardiology Congress 2026
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ dail...
08-27 20:01
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
